461432-22-4

(5-Bromo-2-chlorophenyl)(4-ethoxyphenyl)methanone is an intermediate used in the improved synthesis of Dapagliflozin, a novel selective sodium-glucose co-transporter type II (SGLT2) inhibitor.

Under the protection of nitrogen, 2.1 g of tert-butyldimethylchlorosilane prepared in step 1) was mixed with 5-bromo-2-chlorobenzoyl chloride in anhydrous dichloromethane and stirred for 30 min at 0 to 10 °C. Subsequently, 1.2 mol of phenethyl ether and 1.1 mol of ferric chloride were sequentially added to the reaction system, and the reaction temperature was maintained at 14.7 °C, and the reaction continued to be stirred for 5 hours. After completion of the reaction, the reaction mixture was quenched by pouring it into ice water, extracted with dichloromethane, the organic phase was washed with water, and 31 g of 5-bromo-2-chloro-4'-ethoxy benzophenone (intermediate of dagliflozin) was obtained after concentration in 91.4% yield and 99.49% purity.

[1] Patent: CN107200683, 2017, A. Location in patent: Paragraph 0029; 0035; 0039; 0043; 0047
[2] Patent: CN107417515, 2017, A. Location in patent: Paragraph 0030; 0032; 0034; 0036; 0038; 0040
[3] Patent: CN103739581, 2016, B. Location in patent: Paragraph 0228; 0229
[4] Patent: WO2012/25857, 2012, A1. Location in patent: Page/Page column 20
[5] Patent: CN106316803, 2017, A. Location in patent: Paragraph 0014